Request ConsultationIndia is moving beyond its traditional role as a pharmaceutical manufacturing hub and becoming an important destination for innovation, biotechnology, research, and global pharma partnerships. Strong scientific talent, manufacturing capabilities, AI expertise, and a growing healthcare market are creating new opportunities for global pharmaceutical companies.
India is entering a new phase in the global pharmaceutical and biotechnology industry. For decades, the country has been recognised primarily for generic medicines, vaccines, active pharmaceutical ingredients, contract manufacturing, and cost-efficient healthcare production. However, the global pharmaceutical industry is increasingly looking at India for something beyond cost advantage innovation.
The shift is being driven by a combination of scientific talent, laboratory expertise, manufacturing capabilities, a growing healthcare market, and an expanding biotechnology ecosystem. Global pharmaceutical companies are now exploring India not only as a production destination but also as a potential source of partnerships, research capabilities, acquisitions, clinical development, and new technologies.
The growing interest was highlighted by Eli Lilly Chairman and CEO David Ricks, who said India’s innovative biotech ecosystem holds “tremendous Promise”. He pointed to India’s strong scientific talent, laboratory know-how, and manufacturing capabilities while also acknowledging that the country still faces challenges in research funding and in building a fully developed discovery ecosystem.
Lilly’s interest is particularly significant because the company has become one of the world’s most valuable pharmaceutical companies on the back of medicines such as Mounjaro and Zepbound. Risks said Lilly is exploring opportunities in India across manufacturing, partnerships, research, and potential acquisitions.
This suggests that India’s role in global pharma could be changing from being primarily a manufacturing powerhouse to becoming an increasingly important innovation partner.
Why is India Becoming Important to Global Pharma?
India has traditionally been one of the world’s largest suppliers of generic medicine and pharmaceutical products. Its pharmaceutical industry has developed deep expertise in formulation development active pharmaceutical ingredients, biotechnology, clinical research, analytical testing, and large-scale manufacturing.
However, the next stage of growth is expected to come from innovation
Global pharmaceutical companies are increasingly looking for locations where they can access scientific talent, develop technologies, conduct research, manufacture complex products, and establish long-term partnerships.
India offers several of these advantages
The country has a large pool of scientists and technical professionals, extensive laboratory expertise, established pharmaceutical manufacturing infrastructure, and a growing biotechnology sector. At the same time, its healthcare market is expanding as income rises and demand for advanced therapies increases.
For global pharma companies, this creates a dual opportunity.
India can serve as both a market for innovative medicines and a strategic base for pharmaceutical manufacturing infrastructure and a growing biotechnology sector. At the same
For Generic Manufacturing to Innovation
One of the biggest changes taking place in India’s pharmaceutical sector is the movement from traditional generic manufacturing toward more complex and innovation-driven products.
Indian companies have already expanded into the pharmaceutical industry will depend increasingly on sophisticated technologies.
Biologics, antibody therapies, precision medicine, advanced drug-delivery systems, cell therapies, and new molecular platforms require specific scientific and manufacturing capabilities.
India already has substantial experience in laboratory science and pharmaceutical production. The opportunity now is to connect these capabilities with stronger discovery research and biotechnology entrepreneurship.
This is one reason global companies are beginning to view India differently.
The country is no longer simply a location where medicines can be manufactured at lower costs. It has the potential to become part of the innovation process itself.
India Offers a Strong Scientific Talent Base
Talent is one of India’s biggest advantages.
The country produces a large number of graduates and professionals in pharmaceutical sciences, biotechnology, chemistry, medicine, engineering, data science, and related disciplines.
For multinational pharmaceutical companies, this provides access to a broad workforce capable of supporting research, clinical development, regulatory activities, manufacturing, data analysis, medical writing, and scientific operations.
David Ricks specifically highlighted India’s scientists, talent base, laboratory know-how, and manufacturing capabilities as major strengths of the country’s biotech ecosystems.The growing intersection between biotechnology and technology is also creating new opportunities.
Artificial intelligence, computational biology, genomics, automation, and advanced data analytics are increasingly becoming part of drug discovery and development.
India’s large technology workforce could therefore complement its existing pharmaceutical and biotechnology capabilities.
The Rise of AI in Drug Discovery
Artificial intelligence is expected to play an increasingly important role in pharmaceutical research.
AI can help scientists analyse large datasets, predict molecular behavior, identify potential drug candidates, evaluate biological structures, and improve the efficiency of laboratory experimentation.
However, Lilly’s CEO emphasised that AI is currently more useful for improving the efficiency and speed of existing research processes than for independently discovering breakthrough medicines.
For example, AI can help researchers evaluate large numbers of potential molecules and identify candidates that may have undesirable properties before significant laboratory resources are spent on them.
This creates an opportunity for India
The country already has strengths in both information technology and pharmaceutical sciences. Combining these capabilities could support the development of AI-enabled drug discovery, computational biology, clinical data analysis, and precision medicine.
The future opportunity therefore lies not simply in having AI companies or pharmaceutical companies separately, but in connecting the two ecosystems.
Manufacturing is Becoming More Strategic
Manufacturing remains one of India’s strongest advantages.
However, the nature of pharmaceutical manufacturing is changing.
Global companies increasingly need reliable production networks for biologics, complex medicines, active pharmaceutical ingredients, injectable products, and other high-value therapies.
Lilly already works with manufacturing partners in India through highly integrated arrangements rather than simply purchasing products. According to Ricks, these relationships can involve close technical collaboration and support for supplying important inputs or finished products. Lilly also sees the possibility of establishing its own operations in India.This indicates a broader trend.
Pharmaceutical companies are increasingly trying to build resilient and diversified chains.
India can play an important role in this strategy because it combines manufacturing experience with a large skilled workforce and an established pharmaceutical ecosystem.
India is Also Becoming a Larger Healthcare Market
India is not only attractive because of its ability to manufacture medicines.
Its is also becoming an increasingly important market for innovative therapies.
As household income increases and healthcare awareness improves, demand for advanced medicines is expected to rise.
The growing burden of diabetes, obesity cardiovascular disease, cancer, and other chronic conditions is creating significant for effective therapies.
Lilly’s experience with Mounjaro illustrates this opportunity.
Ricks said the company has seen success with Mounjaro in India and is investing in reaching more patient while working with physicians, hospitals, and other stakeholders, particularly in cardiovascular health.
This creates a valuable combination for global pharma.
India can simultaneously become a market for innovative medicines, a location for manufacturing and a potential source of scientific and biotechnology partnerships.
Cardiometabolic Health Could Become a Major Opportunity
Obesity and diabetes are the among the most important areas attracting pharmaceutical investment globally.
The rapid growth of incretin-based medicines has transformed the obesity treatment market and created a new competitive landscape.
Lilly has positioned itself strongly in this area through Mounjaro and Zepbound and is developing additional medicines aimed at expanding its leadership.
Ricks said Lilly could launch as many as four new products in the weight-loss category over the next four years, highlighting the importance of continued innovation.
India could become particularly important in field because of its large population and significant burden of metabolic diseases.
As innovative therapies become more accessible, pharmaceutical companies will increasingly need local healthcare partnerships, physical education, patient-support systems, and appropriate-use strategies.
This could create opportunities for Indian companies across the broader cardiometabolic ecosystem.
Partnerships Could Become the Next Growth Engine
One of the most important signals from Lilly’s India strategy is its openness to partnerships.
Global pharmaceutical companies do not necessarily need to build every capability internally.
Instead, they can partner with Indian biotechnology companies, research organisations, contract development and manufacturing organisations, technology companies, hospitals, and academic institutions.
These partnerships can provide access to specialized expertise while reducing the time and resources required to build capabilities from scratch.
For Indian biotechnology companies, partnerships with global pharma can provide access to international markets, capital, clinical development expertise, regulatory knowledge, and commercial infrastructure.
This creates a mutually beneficial model.
Global pharma gains access to India’s scientific and manufacturing capabilities, while Indian biotech companies gain pathways to scale their technologies internationally.
Acquisition Interest Could Increase
Partnerships may create a pathway toward acquisitions.
As pharmaceutical companies search for innovative assets, they increasingly look towards biotechnology companies with promising technologies, platforms, molecules, or specialised capabilities.
Lilly’s CEO indicated that Indian biotech companies are on the company’s radar, although India’s ecosystem remains less developed than that of leading biotechnology markets such as the United States and China.
If India’s biotechnology companies continue developing proprietary technologies and innovative drug candidates, acquisition interest could increase.
Potential areas could include:
- Novel drug discovery platforms
- Biological and biosimilars
- Cell and gene therapies
- AI-enabled drug discovery
- Digital health technologies
- Advanced drug delivery
- Contract research and development
- Specialty manufacturing
This could gradually shift India from a primarily services-oriented pharmaceutical ecosystem toward a stronger intellectual property-driven biotechnology ecosystem.
Funding Remains a Major Challenge
Despite the opportunities, India still faces an important limitation, research funding
Ricks highlighted the funding environment as one of the areas where India needs improvement. He also noted that the country lacks some of the ecosystem depth seen in China, particularly around venture funding, clinical trials, animal experiments, and supporting laboratory infrastructure.
This is promising because biotechnology innovation requires significant capital.
A promising scientific idea may require years of laboratory research, preclinical testing, clinical trials, regulatory submission, and manufacturing development before generating commercial return.
Without sufficient early-stage funding, promising discoveries can struggle to progress beyond academic research.
Strengthening venture capital, government funding, translational research programs, university-industry partnerships, and biotechnology incubators could therefore become essential for India’s next phase of growth.
Building a Complete Biotech Ecosystem
Indian’s next challenge is not simply attracting more pharmaceutical investment.
It is building a complete innovation ecosystem.
A mature biotechnology ecosystem requires multiple interconnected components.
- Scientific Research: Universities and research institutes need strong capabilities for basic and translational research.
- Venture Capital: Biotechnology companies require patient capital capable of supporting long development timelines.
- Clinical Research: Efficient clinical-trial infrastructure is essential for converting discoveries into medicines.
- Preclinical Infrastructure: Animal research facilities, laboratories, testing centers, and specialised scientific services must be readily accessible.
- Manufacturing: Innovative products require scalable manufacturing infrastructure that can meet international quality standards.
- Regulatory support: Efficient and predictable regulatory processes can accelerate development while maintaining safety standards.
- Commercialisation: Companies need access to global markets, strategic partners, licensing opportunities, and commercial expertise.
India has many of these components individually. The larger opportunity is to connect them into a more integrated system.
India Compared With China and the United States
India’s opportunity becomes clearer when viewed against other major biotechnology markets.
The United States remains the global leader in biotechnology innovation, supported by deep venture capital markets, world-class universities, major research institutions, and a mature pharmaceutical industry.
China has rapidly strengthened its biotechnology ecosystem through investment in research, clinical trials, laboratories, and biotechnology companies.India has a different set of strengths.
It has a large scientific talent pool, pharmaceutical manufacturing expertise, strong laboratory capabilities, and a major domestic healthcare market.
However, its biotechnology funding and discovery ecosystem still needs further development.
This creates both a challenge and an opportunity.
If India can strengthen the missing pieces, it could become one of the most important biotechnology destinations globally.
Global Pharma Could Help Accelerate India’s Transformation
The increasing involvement of multinational pharmaceutical companies could help strengthen India’s innovation ecosystem.
Global companies bring capital, technical expertise, international regulatory, clinical development experience, manufacturing standards, and access to global markets.
India’s companies, meanwhile, bring local scientific talent, manufacturing expertise, technology capabilities, and knowledge of the domestic healthcare environment.
This combination could create a powerful innovation model.
Instead of global pharma simply outsourcing manufacturing to India, future relationships could increasingly involve joint research, technology development, clinical programs, licensing, co-development, and acquisitions.
That would represent a significant evolution in the India-global pharma relationship.
The Cost and Access Equation
Cost remains an important consideration in India.
Innovative medicines are often expensive because pharmaceutical companies need to recover significant research and development investments.
At the same time, India is a price-sensitive healthcare market where affordability can strongly influence patient access.
Ricks acknowledged the tension between pharmaceutical pricing and the need to fund research. He also noted that lower pricess for obesity medicine could potentially allow more patients to receive treatment.
The long-term opportunity may therefore involve developing innovative medicine while creating pricing and access models suited to different income levels.This could become particularly important as advanced therapies move into emerging markets.
The Future of India’s Pharma Innovation Landscape
The future of India’s Pharmaceutical industry could be defined by a shift from scale and affordability toward innovation and value creation.
The country already possesses many of the foundations required for this transformation.
Its pharmaceutical manufacturing base is well established. Its scientific workforce continues to expand. Its technology sector provides capabilities in artificial intelligence and data science. Its healthcare market is large and increasingly sophisticated.
The missing link is the development of a deeper innovation ecosystem connecting science, capital, clinical research, technology, manufacturing, and commercialization.
If that ecosystem develops, India could become more than a manufacturing destination.
It could become a strategic innovation hub.
What Could the Next Wave of Indian Pharma Innovation Look Like?
The next generation of pharmaceutical innovation in India could emerge across multiple areas.
Biologics and biosimilars could continue expanding as Indian companies build more sophisticated capabilities.
Cell and gene therapies could become increasingly important as manufacturing and clinical infrastructure improves.
AI-driven discovery could connect India’s technology and pharmaceutical sectors.
Precision medicine could benefit from advances in genomics and data analytics.
Advanced manufacturing could strengthen India’s position in complex and high-value medicines.
Contract research and development could evolve from services-based towards deeper co-development partnerships.
Innovative biotechnology companies could attract greater international investment and acquisition interest.
Together, these developments could create a much broader definition of India’s role in global healthcare.
Challenges That Could Slow the Transformation
India’s opportunity is significant, but several challenges must be addressed.
Limited research funding: Early-stage biotechnology companies need greater access to long-term capitalClinical infrastructure: The ecosystem for clinical trials and specialised research needs continued development.Fragmented innovation: Strong needs to retain highly skilled researchers and encourage more scientists to build companies locally.Talent retention: Clear and predictable regulatory pathways can help accelerate innovation.Commercialisation gaps: Scientific discoveries must be translated into products that can reach patient and global markets.
Addressing these challenges will determine whether India can fully realise its biotechnology potential.
The Strategic Shift in Global Pharma
The global pharmaceutical industry is entering a period where innovation is becoming increasingly distributed.
Pharma companies are no longer relying exclusively on traditional research centers in the United States and Europe.
They are exploring new sources of scientific talent, technologies, manufacturing capabilities, and innovative assets across emerging markets.
India is Well Positioned to Benefit from this Shift
The concerns from Lilly’s CEO are important because they reflect how a global pharmaceutical leader views India’s potential. Lilly’s already has a substantial presence in the country, including manufacturing partnerships and a research group in Bengaluru supporting global scientific activities such as regulatory submissions, clinical-trial datasets, publications, and other research activities.
This demonstrates that India’s role can extend well beyond manufacturing.
Conclusion
India is entering a new chapter in the global pharmaceutical and biotechnology industry.
The country has long been recognised for producing medicine efficiently and cost-effectively. The next opportunity is to become a stronger source of scientific innovation, biotechnology development, advanced manufacturing, and global pharmaceutical partnerships.
Eli Lilly CEO David Ricks’ assessment that India’s innovative biotech ecosystem holds tremendous promise highlights the growing international interest in the country. At the same time, his comments also identify the areas that require further development, particularly research funding, clinical infrastructure, and the broader biotechnology ecosystem.
It is about building an environment where Indian scientists can discover new medicines, biotechnology companies can access capital, researchers can conduct sophisticated clinical studies, manufacturers can scale complex products, and global pharmaceutical companies can collaborate with Indian innovators.
The future could see India move from pharmacy of the world to innovation parter for the world.
As global pharma companies search for the the next generation of medicines, technologies, manufacturing capabilities, and scientific talent, India is increasingly becoming part of that search.
The next wave of pharmaceutical innovation may not come from a single country or region.
It may emerges through global collaboration, with India playing an increasingly important role at the center of the ecosystem.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.